All Comments by William Klunk
Go to another page:
- 1
- 2
- In Down's Syndrome, Blood P-Tau217 Detects Plaques and Tangles
- Double Whammy: APP Uppsala Deletion Ups Aβ and Its Aggregation Propensity
- iSILK Tracks Growth of Mouse Plaques at Peptide Level
- In the Wake of COVID-19: Trials Interrupted, Delayed, Cancelled
- Coronavirus Takes Its Toll on Alzheimer’s Clinical Studies
- Topline Result for First DIAN-TU Clinical Trial: Negative on Primary
- Flortaucipir Imaging Distinguishes Alzheimer’s From Other Disorders
- NIH Director Announces $100M Prevention Trial of Genentech Antibody
- 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease.
- Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.
- Brain Aβ Patterns Linked to Brain Energy Metabolism
- Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease.
- PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease.
- Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease.
- Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy.